It is possible that mutations outside of the hotspots may contribute to loss of ACVR2 in primary colon cancer specimens, although in light of the evidence for LOH as well as epigenetic silencing, this is likely to be a less important tumorigenic mechanism. This evidence concerns the gene ACVR2A and malignant colon neoplasm.